EHC · NYSE · STOCK
Encompass Health (EHC) Stock Analysis
$123.21
52W $92.77 – $127.99
62/100
$12.23B
19.8
0.61
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is EHC Bullish or Bearish?
Bullish.
Innellis AI committee rates Encompass Health (EHC) Buy with a composite score of 62/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.90 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.10 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 25.0% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.38 across 8 articles, 14d) — News
Bear Case
- Price-to-book of 4.4x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
62/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 19%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 25.0% shows genuine earnings power backing the valuation
− Price-to-book of 4.4x prices in significant intangible value
Growth Analyst
neutral
52
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
70
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.38 across 8 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 61.7 to 62.1.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
55.5
Neutral
MACD Histogram
-0.058
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$107.86
Resistance
$127.18
Bollinger %B
0.65
Inside Bands
Price vs Moving Averages
EMA 9
$122.42
Above
EMA 21
$122.09
Above
EMA 50
$119.91
Above
EMA 200
$112.63
Above
Fundamental Analysis
Valuation
77
Growth
69
Profitability
79
Financial Health
51
Cash Flow
70
Valuation
P/E Ratio
19.8×
P/B Ratio
4.69×
PEG Ratio
1.00
Dividend Yield
0.63%
52W High
$127.99
52W Low
$92.77
Quality & Growth
ROE
2322.2%
ROA
798.6%
Gross Margin
5450.6%
Operating Margin
1799.8%
Revenue Growth YoY
—
Debt / Equity
1.09
AI Fundamental Assessment
P/E ratio of 19.8 (inexpensive relative to a 15-40x range); Price-to-book of 4.7x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 23.2%; Return on assets of 8.0%; Net margin of 10.0%; Gross margin of 54.5%; Current ratio of 1.19 (tight short-term liquidity); Debt-to-equity of 1.09; Free cash flow per share is positive (4.18); Most recent quarter beat estimates by 3.7%; 5 consecutive earnings beats; EPS growth decelerating (+9.6% -> -3.1% QoQ); Average YoY EPS growth of 10.7%; Analyst estimates rising over recent quarters
Get the Full EHC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →